Comparison of Microwave-Assisted Hydrodistillation and and Traditional Hydrodistillation Methods for the Rosmarinus eriocalyx essential oils from Eastern Morocco
Fadel, O.; Ghazi, K.; Mouni, L.et al.
2011 • In Journal of Materials and Environmental Science, 2 (2)
[en] Volatile compounds of Rosmarinus eriocalyx samples were extracted by steam-hydrodistillation (HD) and microwave-assisted hydrodistillation (MAH). GC-MS and GC-FID analysis of the oils revealed the presence of 22 and 26 compounds in the essential oils obtained through HD and MAH, respectively. The total yield of the volatile fractions obtained through HD and MAH was 1.21% and 1.47%, respectively.
The two oils contained the same dominant components: camphor (35.92% HD; 35.33% MAH), camphene (19.74%; 17.07%), a-pinene (14.53%; 12.87%), and 1,8-cineol (6.52%; 6.73%). Higher amounts of oxygenated monoterpenes such as borneol, 1,8-cineol, isobornyl acetate, a-terpeneol, caryophyllene oxide (13.59%) were present in the oil of MAH in comparison with HD (12.36%). However, HD oil contained more monoterpene hydrocarbons such as tricyclene, a-pinene, camphene, o-cymene and limonene (39.04%) than MAH extracted oil (34.45%).
Wathelet, Jean-Paul ; Université de Liège - ULiège > Chimie et bio-industries > Chimie générale et organique
Asehraou, A.
Charof, R.
Language :
English
Title :
Comparison of Microwave-Assisted Hydrodistillation and and Traditional Hydrodistillation Methods for the Rosmarinus eriocalyx essential oils from Eastern Morocco
Erdmann, F., Lortet-Tieulent, J., Schüz, J., Zeeb, H., Greinert, R., Breitbart, E.W., International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? (2013) Int J Cancer, 132, pp. 385-400. , http://dx.doi.org/10.1002/ijc.27616, PMID:22532371
Diepgen, T.L., Mahler, V., The epidemiology of skin cancer (2002) Br J Dermatol, 146 (SUPPL. 61), pp. 1-6. , http://dx.doi.org/10.1046/j.1365-2133.146.s61.2.x, PMID:11966724
Hauschild, A., Agarwala, S.S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma (2009) J Clin Oncol, 27, pp. 2823-30. , http://dx.doi.org/10.1200/JCO.2007.15.7636, PMID:19349552
Kim, C., Lee, C.W., Kovacic, L., Shah, A., Klasa, R., Savage, K.J., Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide (2010) Oncologist, 15, pp. 765-71. , http://dx.doi.org/10.1634/theoncologist.2009-0237, PMID:20538743
Middleton, M.R., Grob, J.J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma (2000) J Clin Oncol, 18, pp. 158-66. , PMID:10623706
Amaravadi, R.K., Schuchter, L.M., McDermott, D.F., Kramer, A., Giles, L., Gramlich, K., Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases (2009) Clin Cancer Res, 15, pp. 7711-8. , http://dx.doi.org/10.1158/1078-0432.CCR-09-2074, PMID:19996224
Gogas, H.J., Kirkwood, J.M., Sondak, V.K., Chemotherapy for metastatic melanoma: time for a change? (2007) Cancer, 109, pp. 455-64. , http://dx.doi.org/10.1002/cncr.22427, PMID:17200963
Spieth, K., Kaufmann, R., Dummer, R., Garbe, C., Becker, J.C., Hauschild, A., Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG) (2008) Ann Oncol, 19, pp. 801-6. , http://dx.doi.org/10.1093/annonc/mdm565, PMID:18178958
Tarhini, A.A., Kirkwood, J.M., Gooding, W.E., Moschos, S., Agarwala, S.S., A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma (2008) Cancer, 113, pp. 1632-40. , http://dx.doi.org/10.1002/cncr.23791, PMID:18720480
Trinh, V.A., Patel, S.P., Hwu, W.J., The safety of temozolomide in the treatment of malignancies (2009) Expert OpinDrug Saf, 8, pp. 493-9. , http://dx.doi.org/10.1517/14740330902918281, PMID:19435405
Su, Y.B., Sohn, S., Krown, S.E., Livingston, P.O., Wolchok, J.D., Quinn, C., Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications (2004) J Clin Oncol, 22, pp. 610-6. , http://dx.doi.org/10.1200/JCO.2004.07.060, PMID:14726505
Rietschel, P., Wolchok, J.D., Krown, S., Gerst, S., Jungbluth, A.A., Busam, K., Phase II study of extended-dose temozolomide in patients with melanoma (2008) J Clin Oncol, 26, pp. 2299-304. , http://dx.doi.org/10.1200/JCO.2007.14.5292, PMID:18467721
Gajewski, T.F., Cancer immunotherapy (2012) Mol Oncol, 6, pp. 242-50. , http://dx.doi.org/10.1016/j.molonc.2012.01.002, PMID:22248437
Zou, W., Regulatory Tcells, tumour immunity and immunotherapy (2006) Nat Rev Immunol, 6, pp. 295-307. , http://dx.doi.org/10.1038/nri1806, PMID:16557261
Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q., Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy (2011) Clin Cancer Res, 17, pp. 4550-7. , http://dx.doi.org/10.1158/1078-0432.CCR-11-0116, PMID:21498393
Bukowski, R.M., Tendler, C., Cutler, D., Rose, E., Laughlin, M.M., Statkevich, P., Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation (2002) Cancer, 95, pp. 389-96. , http://dx.doi.org/10.1002/cncr.10663, PMID:12124839
Keilholz, U., Scheibenbogen, C., Tilgen, W., Bergmann, L., Weidmann, E., Seither, E., Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials (1993) Cancer, 72, pp. 607-14. , http://dx.doi.org/10.1002/1097-0142(19930715)72:2607::AIDCNCR28207202453.0.CO
2-R, PMID:8319195
Motulsky, H., (2012) GraphPad Prism, Version 5.0. In Statistical analyses for laboratory and clinical researchers
Kleinewietfeld, M., Starke, M., Di Mitri, D., Borsellino, G., Battistini, L., Rötzschke, O., CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells (2009) Blood, 113, pp. 827-36. , http://dx.doi.org/10.1182/blood-2008-04-150524, PMID:18941119
Solito, S., Falisi, E., Diaz-Montero, C.M., Doni, A., Pinton, L., Rosato, A., A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells (2011) Blood, 118, pp. 2254-65. , http://dx.doi.org/10.1182/blood-2010-12-325753, PMID:21734236
Sallusto, F., Geginat, J., Lanzavecchia, A., Central memory and effector memory T cell subsets: function, generation, and maintenance (2004) Annu Rev Immunol, 22, pp. 745-63. , http://dx.doi.org/10.1146/annurev.immunol.22.012703.104702, PMID:15032595
Andersen, R.S., Kvistborg, P., Frøsig, T.M., Pedersen, N.W., Lyngaa, R., Bakker, A.H., Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers (2012) Nat Protoc, 7, pp. 891-902. , http://dx.doi.org/10.1038/nprot.2012.037, PMID:22498709
Andersen, R.S., Thrue, C.A., Junker, N., Lyngaa, R., Donia, M., Ellebæk, E., Dissection of T-cell antigen specificity in human melanoma (2012) Cancer Res, 72, pp. 1642-50. , http://dx.doi.org/10.1158/0008-5472.CAN-11-2614, PMID:22311675
Hadrup, S.R., Bakker, A.H., Shu, C.J., Andersen, R.S., van Veluw, J., Hombrink, P., Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers (2009) Nat Methods, 6, pp. 520-6. , http://dx.doi.org/10.1038/nmeth.1345, PMID:19543285
Vestermark, L.W., Holtved, E., Dahlrot, R., Brimnes, M.K., Svane, I.M., Bastholt, L., A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response (2008) Ecancermedicalscience, 2, p. 91. , PMID:22275974
Dannull, J., Su, Z., Rizzieri, D., Yang, B.K., Coleman, D., Yancey, D., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells (2005) J Clin Invest, 115, pp. 3623-3633. , http://dx.doi.org/10.1172/JCI25947, PMID:16308572
Rasku, M.A., Clem, A.L., Telang, S., Taft, B., Gettings, K., Gragg, H., Transient T cell depletion causes regression of melanoma metastases (2008) J Transl Med, 6, p. 12. , http://dx.doi.org/10.1186/1479-5876-6-12, PMID:18334033
Golovina, T.N., Vonderheide, R.H., Regulatory Tcells: overcoming suppression of T-cell immunity (2010) Cancer J, 16, pp. 342-7. , http://dx.doi.org/10.1097/PPO.0b013e3181eb336d, PMID:20693845
Engell-Noerregaard, L., Ellebæk, E., Iversen, T.Z., Hansen, T.H., Brimnes, M.K., Met, O., Analysis of regulatory T cell phenotype, including CD49d, during treatment of melanoma patients with dendritic cell vaccine, Interleukine-2 and/or metronomic Cyclophosphamide (2011) Clinical and Cellular Immunology, , In press
Kvistborg, P., Shu, C.J., Heemskerk, B., Fankhauser, M., Thrue, C.A., Toebes, M., TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients (2012) Oncoimmunology, 1, pp. 409-18. , http://dx.doi.org/10.4161/onci.18851, PMID:22754759
Galluzzi, L., Senovilla, L., Zitvogel, L., Kroemer, G., The secret ally: immunostimulation by anticancer drugs (2012) Nat Rev Drug Discov, 11, pp. 215-33. , http://dx.doi.org/10.1038/nrd3626, PMID:22301798
Rech, A.J., Mick, R., Kaplan, D.E., Chang, K.M., Domchek, S.M., Vonderheide, R.H., Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer (2010) Cancer Immunol Immunother, 59, pp. 599-607. , http://dx.doi.org/10.1007/s00262-009-0780-x, PMID:19855964
Montero, A.J., Diaz-Montero, C.M., Kyriakopoulos, C.E., Bronte, V., Mandruzzato, S., Myeloid-derived suppressor cells in cancer patients: a clinical perspective (2012) J Immunother, 35, pp. 107-15. , http://dx.doi.org/10.1097/CJI.0b013e318242169f, PMID:22306898
Finkelstein, S.E., Carey, T., Fricke, I., Yu, D., Goetz, D., Gratz, M., Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma (2010) J Immunother, 33, pp. 817-27. , http://dx.doi.org/10.1097/CJI.0b013e3181ecccad, PMID:20842055
Kirkwood, J.M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma (2012) Clin Cancer Res, 18, pp. 555-67. , http://dx.doi.org/10.1158/1078-0432.CCR-11-1491, PMID:22048237
Kyte, J.A., Gaudernack, G., Dueland, S., Trachsel, S., Julsrud, L., Aamdal, S., Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients (2011) Clin Cancer Res, 17, pp. 4568-80. , http://dx.doi.org/10.1158/1078-0432.CCR-11-0184, PMID:21586625
Rodenko, B., Toebes, M., Hadrup, S.R., van Esch, W.J., Molenaar, A.M., Schumacher, T.N., Generation of peptide-MHC class I complexes through UV-mediated ligand exchange (2006) Nat Protoc, 1, pp. 1120-32. , http://dx.doi.org/10.1038/nprot.2006.121, PMID:17406393
